Publications: Prof Michelle Lockley

El-Shakankery KH, Kefas J, Palmer K, Houston A, Mukherjee U, Gao K, Tan W, Crusz SM et al. ( 2024 ) . Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London . Cancers vol. 16 , ( 21 )

Merry E, Kesmez RT, Yu T, Flynn M, Ledermann J, Lockley M, Macdonald N, McCormack M et al. ( 2024 ) . A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population . International Journal of Gynecological Cancer

Oxley S, Ahmed S, Baxter K, Blake D, Braden V, Brincat MR, Bryan S, Dilley J et al. ( 2024 ) . Venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer . International Journal of Gynecological Cancer vol. 34 , ( 11 )

Sullivan SM, Stoneham S, Lockley M, Frazier AL, Billmire DF, Poynter JN ( 2024 ) . Comparison of overall and patterns of care in patients with a malignant ovarian germ cell tumor by age in the United States: a National Cancer Database (2004–2016) analysis . International Journal of Gynecological Cancer

Manchanda R, Sun L, Wei X, legood R ( 2024 ) . Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer . Journal of the National Comprehensive Cancer Network : JNCCN

Pashankar F, Murray MJ, Gell J, MacDonald N, Shamash J, Billmire DF, Klosterkemper L, Olson T et al. ( 2024 ) . Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective . EClinicalMedicine vol. 69 ,

Nuttall Musson E, Miller RE, Mansour MR, Lockley M, Ledermann JA, Payne EM ( 2023 ) . Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy—a role for early monitoring and intervention . Leukemia vol. 38 , ( 1 ) 215 - 218 .

Musson EN, Lockley M, Mansour MR, Miller RE, Lederman J, Payne E ( 2023 ) . Identification, Monitoring and Reversibility of PARP Inhibitor Associated Clonal Haematopoiesis and Myelodysplastic Syndrome: A Case Series . Blood vol. 142 , ( Supplement 1 )

Wood GE, Bunting CP, Veli M, Arora R, Berney DM, Alifrangis C, MacDonald ND, Miller RE et al. ( 2023 ) . Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy . Frontiers in Oncology vol. 13 ,

Travis LB, Feldman DR, Fung C, Poynter JN, Lockley M, Frazier AL ( 2023 ) . Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship . Journal of Clinical Oncology vol. 42 , ( 6 ) 696 - 706 .

Smith P, Bradley T, Gavarró LM, Goranova T, Ennis DP, Mirza HB, De Silva D, Piskorz AM et al. ( 2023 ) . Author Correction: The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma . Nature Communications vol. 14 , ( 1 )

Sobocan M, Chandrasekaran D, Sideris M, Blyuss O, Fierheller C, Kalra A, Sia J, Miller RE et al. ( 2023 ) . Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: A prospective cohort study . BJOG An International Journal of Obstetrics & Gynaecology vol. 131 , ( 6 ) 848 - 857 .

Smith P, Bradley T, Gavarró LM, Goranova T, Ennis DP, Mirza HB, De Silva D, Piskorz AM et al. ( 2023 ) . The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma . Nature Communications vol. 14 , ( 1 )

Puttock EH, Tyler EJ, Manni M, Maniati E, Butterworth C, Burger Ramos M, Peerani E, Hirani P et al. ( 2023 ) . Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis . Nature Communications vol. 14 , ( 1 )

Philpott S, Raikou M, Manchanda R, Lockley M, Singh N, Scott M, Evans DG, Adlard J et al. ( 2022 ) . The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 . Journal of Medical Genetics vol. 60 , ( 5 ) 440 - 449 .

Sobocan M, Chandrasekaran D, Sideris M, Blyuss O, Miller R, Mills-Baldock T, Crusz S, Sun L et al. ( 2022 ) . 2022-RA-1443-ESGO Patient decision aids in genetic testing for women with ovarian cancer . Conference: Vaginal and vulvar cancera463.1 - a4a463 .

Fonseca A, Lobo J, Hazard FK, Gell J, Nicholls PK, Weiss RS, Klosterkemper L, Volchenboum SL et al. ( 2022 ) . Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium . British Journal of Cancer vol. 127 , ( 9 ) 1577 - 1583 .

Palmer KR, El-Shakankery KH, Kefas J, Gao K, Crusz S, Flynn M, Jonathan L, Lockley M et al. ( 2022 ) . 600P Ethnic and socio-economic status in ovarian cancer patients recruited to clinical trials . Annals of Oncology vol. 33 ,

Graham R, Stoneham S, Lockley M, MacDonald ND ( 2022 ) . Letter to Editor in Response to: Controlled Aspiration of Large Paediatric Ovarian Cystic Tumors . Journal of Pediatric Surgery vol. 58 , ( 10 )

Hoare JI, Hockings H, Saxena J, Silva VL, Haughey MJ, Wood GE, Nicolini F, Mirza H et al. ( 2022 ) . A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer . Gynecologic Oncology vol. 167 , ( 1 ) 96 - 106 .

Pashankar F, Hanley K, Lockley M, Stoneham S, Nucci MR, Reyes-Múgica M, Elishaev E, Vang R et al. ( 2022 ) . Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference . European Journal of Cancer vol. 173 , 59 - 70 .

Hockings H, Lockley M, Graham T, Lakatos E, Huang W ( 2022 ) . Abstract B001: Developing adaptive therapy to suppress the evolution of treatment resistance in high-grade serous ovarian cancer . Cancer Research vol. 82 , ( 10_Supplement ) b001 - b001 .

Hockings H, Lockley M, Graham T, Lakatos E, Huang W ( 2022 ) . Abstract PR015: Developing adaptive therapy to suppress the evolution of treatment resistance in high-grade serous ovarian cancer . Cancer Research vol. 82 , ( 10_Supplement ) pr015 - pr015 .

Cheng Z, Mirza H, Ennis DP, Smith P, Gavarró LM, Sokota C, Giannone G, Goranova T et al. ( 2022 ) . The Genomic Landscape of Early-Stage Ovarian High-Grade Serous CarcinomaGenomics of Early-Stage Ovarian High-Grade Serous Carcinoma . Clinical Cancer Research vol. 28 , ( 13 ) of1 - of12 .

Graham R, MacDonald ND, Lockley M, Miller R, Butler J, Murali K, Sarker S-J, Banerjee S et al. ( 2022 ) . Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort study . European Journal of Obstetrics & Gynecology and Reproductive Biology vol. 271 , 138 - 144 .

Hoare JI, Osmani B, O’Sullivan EA, Browne A, Campbell N, Metcalf S, Nicolini F, Saxena J et al. ( 2022 ) . Carvedilol targets β-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy . Communications Biology vol. 5 , ( 1 )

Cheng Z, Mirza HB, Ennis DP, Smith P, Gavarro LM, Sokota C, Giannone G, Goranova T et al. ( 2022 ) . The copy number landscape of early stage ovarian high grade serous carcinoma . CANCER RESEARCH . vol. 82 ,

Philpott S, Raikou M, Manchanda R, Evans G, Edmondson R, Menon U, Ahmed M, Woodward E et al. ( 2021 ) . 423 Results of the avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance program for BRCA mutation-carriers . International Journal of Gynecological Cancer vol. 31 , ( Suppl 3 ) a373 - a374 .

Graham R, Macdonald N, Murali K, Sarker S, Miller R, Banerjee S, Butler J, Stoneham S et al. ( 2021 ) . 414 Surgery for malignant ovarian germ cell tumours: a multicentre retrospective cohort study . Conference: Ovarian cancera234 - a235 .

Oxley SG, Achampong YA, Sambandan N, Hughes DJ, Thomas M, Lockley M, Olaitan A ( 2021 ) . Venous thromboembolism in women with ovarian cancer undergoing neoadjuvant chemotherapy prior to cytoreductive surgery: A retrospective study . Acta Obstetricia Et Gynecologica Scandinavica vol. 100 , ( 11 ) 2091 - 2096 .

Chandrasekaran D, Sobocan M, Blyuss O, Miller RE, Evans O, Crusz SM, Mills-Baldock T, Sun L et al. ( 2021 ) . Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study . Cancers vol. 13 , ( 17 )

Lakatos E, Hockings H, Mossner M, Huang W, Lockley M, Graham TA ( 2021 ) . LiquidCNA: Tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations . iScience vol. 24 , ( 8 )

Lockley M, Stoneham S, Shamash J, Pashankar F, Frazier L ( 2021 ) . Re: ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis’ . European Journal of Cancer vol. 152 , 255 - 256 .

Malacrida B, Nichols S, Maniati E, Jones R, Delanie-Smith R, Roozitalab R, Tyler EJ, Thomas M et al. ( 2021 ) . A human multi-cellular model shows how platelets drive production of diseased extracellular matrix and tissue invasion . iScience vol. 24 , ( 6 )

Silva VL, Saxena J, Nicolini F, Hoare JI, Metcalf S, Martin SA, Lockley M ( 2021 ) . Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer . Cell Death & Disease vol. 12 , ( 4 )

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S et al. ( 2021 ) . Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” Gynecol. Oncol. 154 (2019) 441–448 . Gynecologic Oncology vol. 161 , ( 1 ) 328 - 329 .

Tse WY, Maniati E, Wang J, Lockley M, Martin S . Identification of a novel regulator of FANCD2 mediated DNA Repair . Conference: Proceedings of The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response

Lakatos E, Hockings H, Mossner M, Huang W, Lockley M, Graham TA ( 2021 ) . LiquidCNA: tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations .

Morgan RD, McNeish IA, Cook AD, James EC, Lord R, Dark G, Glasspool RM, Krell J et al. ( 2020 ) . Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial . The Lancet Oncology vol. 22 , ( 2 ) 277 - 288 .

Alifrangis C, Sharma A, Chowdhury S, Duncan S, Milic M, Gogbashian A, Agarwal S, Sahdev A et al. ( 2020 ) . Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients . European Journal of Cancer vol. 164 , 105 - 113 .

Shamash J, Ansell W, Alifrangis C, Thomas B, Wilson P, Stoneham S, Mazhar D, Warren A et al. ( 2020 ) . The impact of a supranetwork multidisciplinary team (SMDT) on decision-making in testicular cancers: a 10-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG) . British Journal of Cancer vol. 124 , ( 2 ) 368 - 374 .

Hoare JI, Hockings H, Saxena J, Silva VL, Maniati E, Mirza HB, Huang W, Wood GE et al. ( 2020 ) . Platinum resistance induces diverse evolutionary trajectories in high grade serous ovarian cancer .

Berney DM, Shamash J, Stoneham S, Lockley M ( 2020 ) . Response to: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice . European Journal of Cancer vol. 130 , 267 - 268 .

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S et al. ( 2020 ) . Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” [Gynecol. Oncol. 154 (2019) 441–448] . Gynecologic Oncology vol. 157 , ( 2 ) 558 - 559 .

Casey L, Powell A, Bohm S, Manchanda R, Lockley M, Kobel M, Singh N ( 2020 ) . Role of Ki67 Proliferation Index and CD8 Tumour-Infitrating Lymphocyte Counts in Predicting Outcome in High-Grade Serous Tubo-Ovarian Carcinoma (HGSC) Showing No/Partial Response to Neoadjuvant Chemotherapy . MODERN PATHOLOGY . vol. 33 , 1024 - 1024 .

Berney DM, Stoneham S, Arora R, Shamash J, Lockley M ( 2019 ) . Ovarian germ cell tumour classification: views from the testis . Histopathology vol. 76 , ( 1 ) 25 - 36 .

McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, Mould T, Side L et al. ( 2019 ) . Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process . International Journal of Gynecological Cancer vol. 30 , ( 2 )

Hockings HA, Mossner M, Lakatos E, Graham T, Lockley M ( 2019 ) . 25P Low pass whole genome sequencing can be used to calculate the relative proportion of chemotherapy resistant disease in high grade serous ovarian cancer . Annals of Oncology . vol. 30 ,

Wood GE, Lockley M, Kermorgant S ( 2019 ) . 68P C-met mediates invasion and chemotherapy resistance in high grade serous ovarian cancer . Annals of Oncology . vol. 30 ,

Hockings H, Wood G, Lockley M ( 2019 ) . EP870 Bevacizumab facilitates surgery in previously inoperable patients with low-grade serous ovarian cancer: a case series . International Journal of Gynecological Cancer . Conference: ePoster vol. 29 ,

Heath O ( 2019 ) . The effects of neo-adjuvant chemotherapy on myeloid cells in high-grade serous ovarian cancer metastases .

Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, Sarker S-J, Lockley M ( 2019 ) . GCT-30 Surgical management of ovarian germ cell tumours . European Urology Open Science vol. 18 , ( 4 )

Shamash J, Ansell W, Alifrangis C, Sahdev A, Thomas B, Wilson P, Mazhar D, Warren A et al. ( 2019 ) . GCT-84 The impact of a supranetwork-multidisciplinary team (SMDT) on decision making in testicular cancers: A ten-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG) . European Urology Open Science vol. 18 , ( 4 )

Heath OM, Maniati E, Belato C, Gopinathan G, Lecker L, Lakhani A, Pegrum C, McDermott J et al. ( 2019 ) . Abstract 1103: The effects of neo-adjuvant chemotherapy on myeloid cells in high-grade serous ovarian cancer metastases . Cancer Research . vol. 79 , 1103 - 1103 .

Saxena J, Nicolini F, Lockley M ( 2019 ) . Abstract 3801: Reversing chemoresistance in high grade serous ovarian cancer . Conference: Experimental and Molecular Therapeutics3801 - 3801 .

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S et al. ( 2019 ) . Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data . Gynecologic Oncology

Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, Sarker S-J, Ledermann J et al. ( 2019 ) . A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice . European Journal of Cancer vol. 113 , 19 - 27 .

Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D et al. ( 2019 ) . Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium . British Journal of Cancer vol. 120 , ( 8 ) 868 - 868 .

Böhm S, Le N, Lockley M, Brockbank E, Faruqi A, Said I, Jeyarajah A, Wuntakal R et al. ( 2019 ) . Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results . International Journal of Gynecological Cancer vol. 29 , ( 2 )

Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley L-A et al. ( 2019 ) . COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA . CLINICAL CANCER RESEARCH . vol. 25 , 64 - 64 .

Lockley M, Stoneham SJ, Olson TA ( 2018 ) . Ovarian cancer in adolescents and young adults . Pediatric Blood & Cancer vol. 66 , ( 3 )

Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley L-A et al. ( 2018 ) . Copy number signatures and mutational processes in ovarian carcinoma . Nature Genetics vol. 50 , ( 9 ) 1262 - 1270 .

Hoare JI, Saxena J, Hockings H, McDermott J, Browne A, Lockley M ( 2018 ) . Abstract A54: Generation and characterization of a novel panel of platinum-resistant HGSOC models . Clinical Cancer Research . vol. 24 , a54 - a54 .

Walton J, Farquharson M, Mason S, Blagih J, Ennis D, Leung E, Dowson S, Athineos D et al. ( 2018 ) . Abstract PR14: CRISPR/Cas9-mediated Trp53, Brca1, Brca2, Pten, and Nf1 knockout to generate improved murine models of ovarian high-grade serous carcinoma . Clinical Cancer Research . vol. 24 , pr14 - pr14 .

Devlin M-J, Chandrasekaran D, Singh N, Ledermann JA, Lockley M, McCormack M, Wilkinson N, Miller R et al. ( 2018 ) . Clear cell ovarian cancer (CCOC): 115 patient (pt) series showing access to experimental therapy may improve response rates in recurrent disease . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) 5581 - 5581 .

Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M, Mould T, Side L ( 2018 ) . Mainstreamed genetic testing for women with ovarian cancer: first-year experience . Journal of Medical Genetics vol. 56 , ( 3 )

Fearon AE, Carter EP, Clayton NS, Wilkes EH, Baker A-M, Kapitonova E, Bakhouche BA, Tanner Y et al. ( 2018 ) . PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer . Cell Reports vol. 22 , ( 9 ) 2469 - 2481 .

Lockley M, Newton C, Murali K, Ahmed A, Hockings H, Berney D, Shamash J, Banerjee S et al. ( 2018 ) . A multicentre analysis of malignant ovarian germ cell tumours: rationale for alignment of paediatric and adult practice and for chemotherapy de-escalation in specific subtypes . INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . vol. 28 , 42 - 43 .

Walton J, Farquharson M, Mason S, Blagih J, Ennis D, Leung E, Dowson S, Athineos D et al. ( 2018 ) . CRISPR/Cas9-mediated <i>Trp53</i>, <i>Brca1</i>, <i>Brca2</i>, <i>Pten</i>, and <i>Nf1</i> knockout to generate improved murine models of ovarian high-grade serous carcinoma . CLINICAL CANCER RESEARCH . vol. 24 , 36 - 37 .

Hoare JI, Saxena J, Hockings H, McDermott J, Browne A, Lockley M ( 2018 ) . Generation and characterization of a novel panel of platinum-resistant HGSOC models . CLINICAL CANCER RESEARCH . vol. 24 , 68 - 68 .

Wood GE, Heuss SF, Osagie I, Lockley M, Kermorgant S ( 2018 ) . c-Met signalling and endocytosis in clear cell ovarian cancer . INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . vol. 28 , 95 - 95 .

Pearce OMT, Delaine-Smith R, Maniati E, Nichols S, Wang J, Böhm S, Rajeeve V, Ullah D et al. ( 2017 ) . Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers . Cancer Discov

Casey L, Köbel M, Ganesan R, Tam S, Prasad R, Böhm S, Lockley M, Jeyarajah AJ et al. ( 2017 ) . A comparison of p53 and WT1 immunohistochemical expression patterns in tubo‐ovarian high‐grade serous carcinoma before and after neoadjuvant chemotherapy . Histopathology vol. 71 , ( 5 ) 736 - 742 .

Walton J, Blagih J, Farquharson M, Ennis D, Leung E, Dowson S, Tookman LA, Orange C et al. ( 2017 ) . Abstract AP24: CRISPR/CAS9–MEDIATED TRP53 , BRCA1 , BRCA2 AND PTEN KNOCKOUT TO GENERATE IMPROVED MURINE MODELS OF OVARIAN HIGH GRADE SEROUS CARCINOMA . Clinical Cancer Research . vol. 23 , ap24 - ap24 .

Glasspool RM, Blagden SP, Lockley M, Paul J, Hopkins C, Thomson F, Brown J, Fernandes R et al. ( 2017 ) . A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours . Journal of Clinical Oncology vol. 35 , ( 15_suppl ) 2594 - 2594 .

Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D et al. ( 2017 ) . Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium . British Journal of Cancer vol. 116 , ( 10 ) 1294 - 1301 .

Ganesan R, Singh N, Casey L, Tam S, Farugi A, Prasad R, Boehm S, Lockley M et al. ( 2017 ) . Immunohistochemical Expression of p53 and WT1 Is Retained Following Chemotherapy in High-Grade Serous Tubo-Ovarian Carcinoma (HGSC) . LABORATORY INVESTIGATION . vol. 97 , 286A - 287A .

McDermott JR, Jones R, Lockley M, Balkwill FR ( 2017 ) . The Chemokine CXCL10 is a Potential Regulator of Cancer Stem Cells in High Grade Serous Carcinoma . JOURNAL OF PATHOLOGY . vol. 243 , S15 - S15 .

La Russa M, Kokka F, Lockley M, Brockbank E ( 2016 ) . Haemorrhagic shock due to spontaneous splenic rupture in a patient subsequently diagnosed with advanced ovarian cancer . J Obstet Gynaecol vol. 37 , ( 2 ) 268 - 270 .

Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C et al. ( 2016 ) . CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinoma . Cancer Research

Montfort A, Pearce OMT, Maniati E, Vincent B, Bixby LM, Bo hm S, Dowe T, Wilkes EH et al. ( 2016 ) . A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases . Clinical Cancer Research

BALKWILL F, Anne Montfort, Oliver Pearce ( 2016 ) . Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma . Clinical Cancer Research

Walton J, Dowson S, Ennis D, Leung E, Farquharson M, Stevenson D, Blyth K, Strathdee D et al. ( 2016 ) . Abstract B53: CRISPR/Cas9 mediated p53 and BRCA2 knockout to generate improved murine models of high grade serous ovarian cancer . Clinical Cancer Research vol. 22 , ( 2_Supplement ) b53 - b53 .

Tookman LA, Browne AK, Connell CM, Bridge G, Ingemarsdotter CK, Dowson S, Shibata A, Lockley M et al. ( 2016 ) . RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer . Molecular Cancer Research vol. 14 , ( 1 ) 44 - 55 .

Montfort A, Boehm S, Dowe T, Topping J, Lockley M, Capasso M, Balkwill F ( 2015 ) . Abstract 455: B cells actively participate to the anti-cancer immune response in high grade serous ovarian cancer metastases . Cancer Research . vol. 75 , 455 - 455 .

Browne A, Tookman LA, Ingemarsdotter CK, Bouwman RD, Pirlo K, Wang Y, McNeish IA, Lockley M ( 2015 ) . Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity . Cancer Research vol. 75 , ( 14 ) 2811 - 2821 .

Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D et al. ( 2015 ) . Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma . Journal of Clinical Oncology vol. 33 , ( 22 ) 2457 - 2463 .

Ingemarsdotter CK, Tookman LA, Browne A, Pirlo K, Cutts R, Chelela C, Khurrum KF, Leung EYL et al. ( 2014 ) . Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control . Molecular Oncology vol. 9 , ( 4 ) 791 - 805 .

Browne AK, Tookman LA, Ingemarsdotter CK, Bouwman R, Pirlo K, Wang Y, Hodivala-Dilke KM, McNeish IA et al. ( 2014 ) . 106 Beta-3 integrin inhibition reduces inflammatory cytokine release but not anti-cancer activity of oncolytic adenovirus in ovarian cancer . European Journal of Cancer . vol. 50 ,

Spurrell EL, Lockley M ( 2014 ) . Adaptive immunity in cancer immunology and therapeutics . Ecancermedicalscience vol. 8 ,

Leinster DA, Colom B, Whiteford JR, Ennis DP, Lockley M, McNeish IA, Aurrand-Lions M, Chavakis T et al. ( 2013 ) . Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer . FASEB J vol. 27 , ( 10 ) 4244 - 4253 .

Boehm S, Ennis D, Dowe T, Canosa M, McNeish I, Lockley M, Balkwill F ( 2013 ) . Tumour-associated inflammatory cytokines are reduced following primary platinum-based chemotherapy in plasma of high-grade serous ovarian cancer patients . EUROPEAN JOURNAL OF CANCER . vol. 49 , S736 - S736 .

Rockall AG, Avril NE, Lam R, Mozley PD, Iannone R, Lockley M, Parkinson C, McNeish IA et al. ( 2013 ) . [18F]Fluorodeoxyglucose PET and Volumetric CT analysis are early biomarkers of survival in platinum-sensitive relapsed ovarian cancer - a multicentre trial . EUROPEAN JOURNAL OF CANCER . vol. 49 , S735 - S735 .

Young A-M, Archibald KM, Tookman LA, Pool A, Dudek K, Jones C, Williams SL, Pirlo KJ et al. ( 2012 ) . Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo . Mol Ther vol. 20 , ( 9 ) 1676 - 1688 .

Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FNE, Cooper D, Gould D et al. ( 2012 ) . The peritoneal tumour microenvironment of high-grade serous ovarian cancer . J Pathol vol. 227 , ( 2 ) 136 - 145 .

Brais RJ, Davies SE, O'Donovan M, Simpson BW, Cook N, Darbonne WC, Chilcott S, Lolkema MP et al. ( 2012 ) . Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials . PANCREATOLOGY vol. 12 , ( 1 ) 8 - 15 .

Schultes BC, Lolkema MPJK, Chu CL, Zhou H, Long A, Lockley M, Avery W, Kurtagic E et al. ( 2012 ) . M402, a heparan sulfate mimetic and novel candidate for the treatment of pancreatic cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 30 ,

Connell CM, Shibata A, Tookman LA, Archibald KM, Flak MB, Pirlo KJ, Lockley M, Wheatley SP et al. ( 2011 ) . Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells . J Clin Invest vol. 121 , ( 4 ) 1283 - 1297 .

Salako MA, Kulbe H, Ingemarsdotter CK, Pirlo KJ, Williams SL, Lockley M, Balkwill FR, McNeish IA ( 2011 ) . Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression . Mol Ther vol. 19 , ( 3 ) 490 - 499 .

Connell CM, Shibata A, Tookman L, Archibald KM, Flak MB, Pirlo KJ, Lockley M, Wheatley SP et al. ( 2011 ) . Genomic DNA damage and ATR-Chk1 signalling determine adenovirus oncolytic efficacy in ovarian cancer . HUMAN GENE THERAPY vol. 22 , ( 10 ) A113 - A113 .

Flak MB, Connell CM, Chelala C, Archibald K, Salako MA, Pirlo KJ, Lockley M, Wheatley SP et al. ( 2010 ) . p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker . Mol Cancer vol. 9 ,

Salako MA, Connell CM, Shibata A, Graupner V, Lockley M, Balkwill FR, McNeish IA ( 2010 ) . Abstract 591: Host cell DNA damage and inflammation responses determine oncolytic adenovirus efficacy in ovarian cancer . Cancer Research . vol. 70 , 591 - 591 .

Lolkema M, Lockley M, Zhou H, Duffner J, Kishomoto TK, Tuveson DA ( 2010 ) . Abstract LB-43: M402, a novel heparin sulphate mimetic, synergizes with gemcitabine to improve survival and reduce metastasis and epithelial-to-mesenchymal transition (EMT) in a genetically engineered mouse model for pancreatic cancer . Cancer Research vol. 70 , ( 8_Supplement )

Lockley M, Eisen T ( 2009 ) . Sorafenib: a multitargeted oral agent for the treatment of advanced renal cell cancer . Journal of clinical practice vol. 6 , ( 1 ) 111 - 124 .

Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR, McNeish IA ( 2008 ) . Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer . Oncogene vol. 27 , ( 22 ) 3081 - 3090 .

Baird SK, Ingemarsdotter CK, Eddaoudi A, Lockley M, Lemoine NR, McNeish IA ( 2008 ) . Oncolytic adenoviral mutants define a novel mode of programmed cell death in ovarian cancer . HUMAN GENE THERAPY . vol. 19 , 399 - 399 .

Leyton J, Lockley M, Aerts JL, Baird SK, Aboagye EO, Lemoine NR, McNeish IA ( 2006 ) . Quantifying the activity of adenoviral E1A CR2 deletion mutants using Renilla luciferase bioluminescence and 3 '-deoxy-3 '-[F-18] fluorothymidine positron emission tomography imaging . CANCER RES vol. 66 , ( 18 ) 9178 - 9185 .

Lockley M, Fernandez M, Wang Y, Li NF, Conroy S, Lemoine N, McNeish I ( 2006 ) . Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin . Cancer Res vol. 66 , ( 2 ) 989 - 998 .

Baird SK, Lockley M, Leyton J, Aboagye EO, Lemoine NR, McNeish IA ( 2006 ) . E1A CR2 deletion mutant adenoviral vectors in ovarian cancer: combination with apoptosis inducers and monitoring with [18F] FLT-PET imaging . CANCER RESEARCH . vol. 66 ,

McNeish IA, Lopes R, Bell SJ, McKay TR, Fernandez M, Lockley M, Wheatley SP, Lemoine NR ( 2005 ) . Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis . Exp Cell Res vol. 302 , ( 1 ) 69 - 82 .

Oakervee HE, Gordon AC, Kaya B, Taussig DC, Lockley M, Barnett MJ, Rohatiner AZS, Lister TA et al. ( 2002 ) . Outcomes of critical illness in patients with haematological malignancy . BLOOD . vol. 100 , 875A - 876A .